Experimental Pill Added to Chemo Shrinks Tumors in Most Pancreatic Cancer Patients

Experimental Pill Added to Chemo Shrinks Tumors in Most Pancreatic Cancer Patients

Follow America's fastest-growing news aggregator, Spreely News, and stay informed. You can find all of our articles plus information from your favorite Conservative voices. 

An experimental daily pill combined with standard chemotherapy shrank tumors or stopped their growth in the vast majority of patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at the EORTC-NCI-AACR Symposium in Barcelona.

The phase 1/2 trial tested daraxonrasib, an oral drug developed by California-based Revolution Medicines, paired with two standard IV chemotherapy drugs, gemcitabine and nab-paclitaxel. Researchers tracked 61 patients whose pancreatic cancer had already spread to other organs and who had not yet been treated for the advanced disease.

Pancreatic cancer ranks among the hardest cancers to treat. More than half of patients are diagnosed only after the disease has spread, and standard chemotherapy alone typically shrinks tumors in just 23% to 42% of cases before the cancer resumes growing, usually within five to six months. Most patients with metastatic disease survive 8 to 11 months, and government data shows only about 3% live five years past diagnosis.

The new combination performed far better over a median follow-up of 18 months. Tumors shrank in 60.7% of patients, including complete disappearance on scans in 8.2% of cases. Overall, the treatment stopped tumor growth in 90.2% of participants.

Patients went a median of 12.8 months before their cancer worsened — nearly double what standard chemotherapy typically delivers — and 76.6% were still alive after one year.

“We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year,” said Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who led the study.

More than 90% of pancreatic cancers are driven by a mutated gene called RAS that fuels tumor growth. Daraxonrasib is built to shut off that signal — a feat scientists long believed drugs couldn’t accomplish.

Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the study, said the results show RAS-targeted drugs can be paired with existing treatments from the start of care to potentially produce longer-lasting benefits.

Side effects included rash, diarrhea, fatigue and low blood cell counts tied to chemotherapy, most of them manageable with standard care. Only 5% of patients stopped treatment because of side effects linked specifically to daraxonrasib.

The study has real limits. It was a small, early-phase trial with no comparison group — every one of the 61 patients received the experimental combination, so doctors cannot yet say definitively how much better it performs against chemotherapy alone, or whether it extends overall survival. The findings also apply only to metastatic pancreatic cancer, even though RAS mutations drive other cancers including certain lung, colorectal and gynecological cancers; those would require separate trials.

To settle the survival question, researchers have launched a larger, randomized Phase 3 trial called RASolute-303, which will directly compare daraxonrasib — alone and combined with chemotherapy — against standard chemotherapy alone.

Share:

GET MORE STORIES LIKE THIS

IN YOUR INBOX!

Sign up for our daily email and get the stories everyone is talking about.

Discover more from Liberty One News

Subscribe now to keep reading and get access to the full archive.

Continue reading